FDA DEVICE FACTS
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)
Anumana, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The ECG-AI PH 12-Lead Algorithm is software intended to aid in earlier detection of elevated mean pulmonary arterial pressure (mPAP), an indicator of pulmonary hypertension, in adults presenting with dyspnea. The ECG-AI PH 12-Lead Algorithm is not intended to be a stand-alone diagnostic device for pulmonary hypertension or to replace current clinical practice guidelines. A positive result may suggest the need for further clinical evaluation. Additionally, if the patient is at high risk for pulmonary hypertension, a negative result should not rule out additional clinical evaluation. The ECG-AI PH 12-Lead Algorithm should be applied jointly with clinician judgment. The ECG-AI PH 12-Lead Algorithm should not be used on ECGs from adults with an implanted pacemaker or on ECGs with a paced rhythm.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。